Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Why does labetalol fail in severe preeclampsia? new study aims to find out

NCT ID NCT07547046

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

Severe preeclampsia is a dangerous pregnancy complication that can cause high blood pressure, harming both mother and baby. This observational study will follow 350 women to identify factors that make blood pressure control with the drug labetalol fail. By understanding these factors, doctors hope to predict treatment failure and adjust care more quickly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
labetalol
What this could lead to
If successful, this study could help doctors identify which women with severe preeclampsia are less likely to respond to labetalol, allowing for faster, more personalized treatment.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. It may only identify associations, not causes, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult pregnant women with severe preeclampsia requiring intravenous labetalol as part of routine clinical care.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient (age ≥ 18 years) * Pregnancy ≥ 24 weeks of gestation with one or more viable fetuses and severe preeclampsia requiring intravenous labetalol administration, either as continuous infusion (IVSE) or intravenous bolus titration Exclusion Criteria: * Contraindication to labetalol (asthma, chronic obstructive pulmonary disease, bradycardia, current or history of intracardiac conduction disorders, or history of hypersensitivity reaction) * Intravenous antihypertensive treatment initiated prior to inclusion * Patient refusal or objection to the use of her healthcare data for research purposes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe preeclampsia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

preeclampsia severe pre-eclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe preeclampsia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Agen-Nerac

    Nérac, France

  • CH de Roubaix

    Roubaix, France

  • CHRU Nancy

    Nancy, France

  • CHU Bordeaux

    Bordeaux, France

  • CHU Carémeau

    Nîmes, France

  • CHU Clermont-Ferrand

    Clermont-Ferrand, France

  • CHU Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant

    Lyon, France

  • CHU Lille

    Lille, France

  • CHU Martinique

    Martigues, France

  • Hôpital Antoine Béclère

    Clamart, France

  • Hôpital Armand-Trousseau

    Paris, France

  • Hôpital Bicêtre

    Le Kremlin-Bicêtre, France

  • Hôpital Cochin Port Royal

    Paris, France

  • Hôpital Necker

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.